Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15118799 | 1.00 | NR1I2 (0.33) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL102059 | 1.00 | NR1I2 (0.33) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL15498374 | 1.00 | NR1I2 (0.33) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL10193051 | 0.95 | NR1I2 (0.32) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL2106005 | 0.92 | NR1I2 (0.33) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL2611975 | 0.92 | NR1I2 (0.33) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL2106004 | 0.92 | NR1I2 (0.33) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL2107311 | 0.92 | NR1I2 (0.33) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL102062 | 0.89 | NR1I2 (0.34) | NR1I2KDM4EHTTATMALDH1A1 | |
| SCHEMBL139398 | 0.89 | NR1I2 (0.34) | NR1I2KDM4EHTTATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235703-A1 | THIOPHENE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235704-A1 | THIOPHENE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235705-A1 | FORMULATIONS OF THIOPHENE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-21 | — | — | US | disclosed |
| US-8674118-B2 | Compounds and methods for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| US-8658674-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130183266-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2104674-B1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-1879879-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2013-03-27 | — | — | EP | disclosed |
| EP-2559691-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | disclosed |
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals ( Canada) Incorporated (CA) | 2012-03-08 | — | — | US | disclosed |
| US-8003685-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2011-08-23 | — | — | US | disclosed |
| US-20100093775-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| EP-2104674-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2009-09-30 | — | — | EP | disclosed |
| US-7569600-B2 | Compounds and methods for the treatment of prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2009-08-04 | — | — | US | disclosed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | disclosed |
| WO-2008058393-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| EP-1879879-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-12-07 | — | — | US | disclosed |
| WO-2006119646-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885KDM4E 1474/4885HTT 1666/4885 |
| US-20100093775-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | ZC3HAV1, YBX1, HAX1 | NR1I2 441/4885KDM4E 2984/4885HTT 2328/4885 |
| US-20140235705-A1 | FORMULATIONS OF THIOPHENE COMPOUNDS | TPMT, NAT1, TST | NR1I2 1643/4885KDM4E 3280/4885HTT 7/4885 |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885KDM4E 1474/4885HTT 1666/4885 |
| US-20140235703-A1 | THIOPHENE COMPOUNDS | MAP3K1, MAPK1, PEAK1 | NR1I2 1415/4885KDM4E 551/4885HTT 2529/4885 |
| US-20130183266-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, CEL, HAVCR2 | NR1I2 1026/4885KDM4E 4612/4885HTT 2392/4885 |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | GOT1, RNASE1, SLC10A1 | NR1I2 1347/4885KDM4E 4110/4885HTT 1456/4885 |
| US-20140235704-A1 | THIOPHENE COMPOUNDS | NAMPT, NAPRT, SLC29A1 | NR1I2 1855/4885KDM4E 2874/4885HTT 381/4885 |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, YBX1, HAX1 | NR1I2 441/4885KDM4E 2984/4885HTT 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.